Stock IDYA IDEAYA BIOSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News IDEAYA Biosciences, Inc.

Equities

IDYA

US45166A1025

Real-time Estimate Cboe BZX
Other stock markets
 02:45:53 2024-04-29 pm EDT 		5-day change 1st Jan Change
40.54 USD +1.50% Intraday chart for IDEAYA Biosciences, Inc. +7.90% +14.00%
Apr. 22 IDEAYA Biosciences Selects Move-Forward Expansion Dose for Mid-Stage Trial of IDE397 Monotherapy MT
Apr. 22 IDEAYA Biosciences, Inc. Announces Selection of Move-Forward Phase 2 Expansion Dose for IDE397 Monotherapy in MTAP-Deletion Squamous Non-Small Cell Lung Cancer CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(4) - April 26, 2024
AQ
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PR
IDEAYA Biosciences Announces ASCO 2024 Oral Presentation for Darovasertib in Neoadjuvant Uveal Melanoma Phase 2 Investigator Sponsored Study
AQ
IDEAYA Biosciences Selects Move-Forward Expansion Dose for Mid-Stage Trial of IDE397 Monotherapy
MT
IDEAYA Biosciences Announces Selection of Move-Forward Phase 2 Expansion Dose for IDE397 Monotherapy in MTAP-Deletion Squamous Non-Small Cell Lung Cancer
PR
IDEAYA Biosciences, Inc. Announces Selection of Move-Forward Phase 2 Expansion Dose for IDE397 Monotherapy in MTAP-Deletion Squamous Non-Small Cell Lung Cancer
CI
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(4)
AQ
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PR
IDEAYA Biosciences to Participate in Upcoming April 2024 Investor Relations Event
PR
Citigroup Raises IDEAYA Biosciences' Price Target to $60 From $40, Maintains Buy Rating
MT
IDEAYA Announces Clinical Collaboration to Evaluate IDE161 in Combination with KEYTRUDA in Patients with Endometrial Cancer
AQ
IDEAYA Biosciences, Merck Sign Deal to Evaluate IDE161 in Combination with Keytruda to Treat Endometrial Cancer Patients
MT
IDEAYA Announces Clinical Collaboration to Evaluate IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer
PR
IDEAYA Biosciences, Inc. Announces Clinical Collaboration to Evaluate Ide161 in Combination with KEYTRUDA (Pembrolizumab) in Patients with Endometrial Cancer
CI
BTIG Starts Coverage on IDEAYA Biosciences With Buy Rating, $55 Price Target
MT
IDEAYA Biosciences to Participate in Upcoming March 2024 Investor Relations Events
PR
Transcript : IDEAYA Biosciences, Inc. Presents at Citi 2024 Virtual Oncology Leadership Summit, Feb-21-2024 08:00 AM
RBC Raises Price Target on IDEAYA Biosciences to $53 From $43 on 'Clarity & Confidence on Daro's Potential,' Keeps Outperform Rating, Speculative Risk
MT
Wedbush Raises IDEAYA Biosciences' PT to $52 From $46, Updates Model to Include Recent Financings; Keeps Outperform Rating
MT
IDEAYA Biosciences Q4 Loss Widens, Revenue Declines
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IDYA Stock
  4. News IDEAYA Biosciences, Inc.